For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Tevogen Bio Holdings Inc’s stock clocked out at $1.16, down -2.52% from its previous closing price of $1.19. In other words, the price has decreased by -$2.52 from its previous closing price. On the day, 1.6 million shares were traded.
Ratios:
To gain a deeper understanding of TVGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, D. Boral Capital on March 04, 2025, initiated with a Buy rating and assigned the stock a target price of $10.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Flomenberg Neal sold 232,968 shares for $1.09 per share. The transaction valued at 253,935 led to the insider holds 3,595,608 shares of the business.
Flomenberg Neal sold 71,273 shares of TVGN for $81,251 on Mar 07 ’25. The insider now owns 3,969,212 shares after completing the transaction at $1.14 per share. On Mar 10 ’25, another insider, Flomenberg Neal, who serves as the insider of the company, sold 70,384 shares for $1.09 each. As a result, the insider received 76,719 and left with 3,898,828 shares of the company.
Stock Price History:
Over the past 52 weeks, TVGN has reached a high of $3.09, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 7.15%, while the 200-Day Moving Average is calculated to be 6.52%.
Shares Statistics:
A total of 177.99M shares are outstanding, with a floating share count of 26.87M. Insiders hold about 85.39% of the company’s shares, while institutions hold 1.94% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
